Company intelligence / Profile preview

Concert Pharmaceuticals

Lexington, Massachusetts, United Statesconcertpharma.com ↗

Ownership: Private
Employees: ~34
Development stage: Other

Overview

Concert Pharmaceuticals developed deuruxolitinib (CTP‑543), a novel oral deuterated JAK1/2 inhibitor. The company successfully completed two pivotal Phase 3 trials in adults with moderate to severe alopecia areata. Deuruxolitinib received Breakthrough Therapy Designation from the FDA for this indication. The company was acquired by Sun Pharma in March 2023

Therapeutic areas: Dermatology
Modalities: small molecules (notably deuterated small molecules)
Industry: Biotech

Partnerships

Sun Pharma (acquirer)prior investors included RA Capital Management, BVF Partners, Jefferies, GSK among others

Beyond the preview

Go deeper on Concert Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Concert Pharmaceuticals.